Jeremy Cetnar

Clinical trials

• Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  Principal investigator · Recruiting · Phase 3

  National Cancer Institute (NCI)

  2025–2039
• Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer

  Principal investigator · Unknown · Phase 1, Phase 2

  Adamis Pharmaceuticals Corporation

  2011–2017
• Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

  Site PI · Recruiting · Phase 2

  National Cancer Institute (NCI)

  2026–2027
• Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  Site PI · Recruiting · Phase 2, Phase 3

  SWOG Cancer Research Network

  2025–2028